{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:31:55Z","timestamp":1785209515917,"version":"3.55.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","rbmojournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reproductive BioMedicine Online"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.rbmo.2018.04.040","type":"journal-article","created":{"date-parts":[[2018,4,21]],"date-time":"2018-04-21T17:35:10Z","timestamp":1524332110000},"page":"216-223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review"],"prefix":"10.1016","volume":"37","author":[{"given":"Jacques","family":"Donnez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9311-2105","authenticated-orcid":false,"given":"Guillaume E.","family":"Courtoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Donnez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Madeleine","family":"Dolmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rbmo.2018.04.040_bib0010","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jogc.2015.11.005","article-title":"Use of ulipristal acetate for the management of fibroid-related acute abnormal uterine bleeding","volume":"38","author":"Arendas","year":"2016","journal-title":"J. Obstet. Gynaecol. Can"},{"key":"10.1016\/j.rbmo.2018.04.040_bib9000","series-title":"Mirena: summary of product characteristics","author":"Bayer","year":"2018"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0020","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/1471-0528.12147","article-title":"Continuation of pregnancy after first-trimester exposure to mifepristone: an observational prospective study","volume":"120","author":"Bernard","year":"2013","journal-title":"BJOG"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0025","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1586\/17446651.2014.862495","article-title":"The potential of selective progesterone receptor modulators for the treatment of uterine fibroids","volume":"9","author":"Bestel","year":"2014","journal-title":"Expert. Rev. Endocrinol. Metab."},{"key":"10.1016\/j.rbmo.2018.04.040_bib0030","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3109\/09513590.2014.950647","article-title":"Selective progesterone receptor modulators: A class with multiple actions and applications in reproductive endocrinology, and gynecology","volume":"30","author":"Bouchard","year":"2014","journal-title":"Gynecol. Endocrinol"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0035","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bpobgyn.2016.12.002","article-title":"The history and use of the progesterone receptor modulator ulipristal acetate for heavy menstrual bleeding with uterine fibroids","volume":"40","author":"Bouchard","year":"2016","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0040","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/humupd\/dmi002","article-title":"Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications","volume":"11","author":"Chabbert-Buffet","year":"2005","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0045","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.fertnstert.2014.07.1238","article-title":"Fibroid growth and medical options for treatment","volume":"102","author":"Chabbert-Buffet","year":"2014","journal-title":"Fertil. Steril"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0050","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.fertnstert.2015.04.025","article-title":"In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment","volume":"104","author":"Courtoy","year":"2015","journal-title":"Fertil. Steril"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0055","doi-asserted-by":"crossref","unstructured":"Courtoy, G.E., Donnez, J., Ambroise, J., Arriagada, P., Luyckx, M., Marbaix, E., Dolmans, M.M., accepted. Gene expression changes in uterine myomas in response to ulipristal acetate treatment. Reproductive BioMedicine Online.","DOI":"10.1016\/j.rbmo.2018.04.050"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0060","doi-asserted-by":"crossref","DOI":"10.1159\/000480011","article-title":"Progesterone receptor isoforms, nuclear corepressor-1 and steroid receptor coactivator-1 and b-cell lymphoma 2 and akt and akt phosphorylation status in uterine myomas after ulipristal acetate treatment: a systematic immunohistochemical evaluation","author":"Courtoy","year":"2017","journal-title":"Gynecol. Obstet. Invest"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0065","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2017-02295","article-title":"Matrix metalloproteinase activity correlates with uterine myoma volume reduction after ulipristal acetate treatment","author":"Courtoy","year":"2018","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0070","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/humupd\/dmw023","article-title":"Uterine fibroid management: from the present to the future","volume":"22","author":"Donnez","year":"2016","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0075","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0015-0282(16)60723-9","article-title":"Treatment of uterine fibroids with implants of gonadotrophin-releasing hormone agonist: assessment by hysterography","volume":"51","author":"Donnez","year":"1989","journal-title":"Fertil. Steril"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0080","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJMoa1103182","article-title":"Ulipristal acetate versus placebo for fibroid treatment before surgery","volume":"366","author":"Donnez","year":"2012","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0085","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa1103180","article-title":"Ulipristal acetate versus leuprolide acetate for uterine fibroids","volume":"366","author":"Donnez","year":"2012","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0090","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.fertnstert.2014.02.008","article-title":"Long-term treatment of uterine fibroids with ulipristal acetate","volume":"101","author":"Donnez","year":"2014","journal-title":"Fertil. Steril"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0095","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/GCO.0000000000000229","article-title":"Current management of myomas: the place of medical therapy with the advent of selective progesterone receptor modulators","volume":"27","author":"Donnez","year":"2015","journal-title":"Curr. Opin. Obstet. Gynecol"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0100","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.fertnstert.2014.10.038","article-title":"Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids","volume":"103","author":"Donnez","year":"2015","journal-title":"Fertil. Steril"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0105","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1080\/14740338.2016.1248943","article-title":"Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate","volume":"15","author":"Donnez","year":"2016","journal-title":"Expert Opin. Drug Saf"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0110","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.fertnstert.2015.09.032","article-title":"Long-term medical management of uterine fibroids with ulipristal acetate","volume":"105","author":"Donnez","year":"2016","journal-title":"Fertil. Steril"},{"key":"10.1016\/j.rbmo.2018.04.040_bib9005","author":"European Medicines Agency (EMA)"},{"key":"10.1016\/j.rbmo.2018.04.040_bib9010","author":"European Medicines Agency (EMA\/97889\/2018)"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173523","article-title":"Safety after extended repeated use of ulipristal acetate for uterine fibroids","volume":"12","author":"Fauser","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0130","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejogrb.2016.11.003","article-title":"Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: premya study results","volume":"208","author":"Fernandez","year":"2017","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/09513590.2013.774591","article-title":"Emergency contraception","volume":"29","author":"Gemzell-Danielsson","year":"2013","journal-title":"Gynecol. Endocrinol"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0140","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1471-0528.1990.tb16249.x","article-title":"Assessment of menstrual blood loss using a pictorial chart","volume":"97","author":"Higham","year":"1990","journal-title":"Br. J. Obstet. Gynaecol"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0145","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/jcpt.12590","article-title":"Spontaneous pregnancy during ulipristal acetate treatment of giant uterine leiomyoma","volume":"43","author":"Hrgovic","year":"2018","journal-title":"J. Clin. Pharm. Ther"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0150","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.mce.2011.05.044","article-title":"The role of progesterone signaling in the pathogenesis of uterine leiomyoma","volume":"358","author":"Kim","year":"2012","journal-title":"Mol. Cell. Endocrinol"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0155","doi-asserted-by":"crossref","first-page":"h4887","DOI":"10.1136\/bmj.h4887","article-title":"Fibroids: diagnosis and management","volume":"351","author":"Lumsden","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0160","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.fertnstert.2014.07.1253","article-title":"First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids","volume":"102","author":"Luyckx","year":"2014","journal-title":"Fertil. Steril"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0165","first-page":"15","article-title":"Repeated-intermittent use of ulipristal acetate for the management of uterine fibroids: an italian pharmacoeconomic evaluation","volume":"68","author":"Maratea","year":"2016","journal-title":"Minerva Ginecol."},{"key":"10.1016\/j.rbmo.2018.04.040_bib0170","article-title":"Successful pregnancy after treatment with ulipristal acetate for uterine fibroids","volume":"2014","author":"Monle\u00f3n","year":"2014","journal-title":"Case. Rep. Obstet. Gynecol"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/humupd\/dmu048","article-title":"Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications","volume":"21","author":"Moravek","year":"2015","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0180","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.fertnstert.2009.09.048","article-title":"Levonorgestrel-releasing intrauterine device insertion ameliorates leiomyoma-dependent menorrhagia among women of reproductive age without a significant regression in the uterine and leiomyoma volumes","volume":"94","author":"Murat Naki","year":"2010","journal-title":"Fertil. Steril"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0185","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/modpathol.2008.19","article-title":"The spectrum of endometrial pathology induced by progesterone receptor modulators","volume":"21","author":"Mutter","year":"2008","journal-title":"Mod. Pathol"},{"key":"10.1016\/j.rbmo.2018.04.040_bib9015","author":"National Institute for Health and Care Excellence (NICE) guideline (NG88)"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0190","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.fertnstert.2010.09.059","article-title":"Efficacy and tolerability of cdb-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase iib study","volume":"95","author":"Nieman","year":"2011","journal-title":"Fertil. Steril"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0195","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/humrep\/14.11.2844","article-title":"Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors a and b in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy","volume":"14","author":"Nisolle","year":"1999","journal-title":"Hum. Reprod"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0205","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijgo.2010.08.009","article-title":"A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia","volume":"112","author":"Sayed","year":"2011","journal-title":"Int. J. Gynaecol. Obstet"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0210","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/GCO.0b013e32832e07e8","article-title":"Clinical utility of progesterone receptor modulators and their effect on the endometrium","volume":"21","author":"Spitz","year":"2009","journal-title":"Curr. Opin. Obstet. Gynecol"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0215","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1056\/NEJMcp1411029","article-title":"Clinical practice. Uterine fibroids","volume":"372","author":"Stewart","year":"2015","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0220","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1080\/01443610400009543","article-title":"Medical management of uterine fibroids with medroxyprogesterone acetate (depo provera): a pilot study","volume":"24","author":"Venkatachalam","year":"2004","journal-title":"J. Obstet. Gynaecol"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0225","first-page":"531","article-title":"Selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on the human endometrium","volume":"32","author":"Whitaker","year":"2017","journal-title":"Hum. Reprod"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0230","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/PGP.0b013e318251035b","article-title":"Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate","volume":"31","author":"Williams","year":"2012","journal-title":"Int. J. Gynecol. Pathol"},{"key":"10.1016\/j.rbmo.2018.04.040_bib0235","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/GRF.0000000000000164","article-title":"Epidemiology of uterine fibroids: from menarche to menopause","volume":"59","author":"Wise","year":"2016","journal-title":"Clin. Obstet. Gynecol"}],"container-title":["Reproductive BioMedicine Online"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472648318301901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472648318301901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T16:37:26Z","timestamp":1661013446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472648318301901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1472648318301901"],"URL":"https:\/\/doi.org\/10.1016\/j.rbmo.2018.04.040","relation":{},"ISSN":["1472-6483"],"issn-type":[{"value":"1472-6483","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review","name":"articletitle","label":"Article Title"},{"value":"Reproductive BioMedicine Online","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rbmo.2018.04.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}